Table 1.
Study characteristics of the association between the rs10069690 polymorphism and cancer risk in this meta‐analysis
| Study (y) | Cancer type | Ethnicity | Method | Source of control | Case | Control | OR (95% CI) | Score |
|---|---|---|---|---|---|---|---|---|
| Zhang et al. (2019) | GCA | Asian | MassArray | HB | 1,024 | 1,118 | 1.42 (1.22–1.66) | 10 |
| Gudmundsson et al. (2017) | Thyroid cancer | European | Illumina | Multiple | 3,001 | 287,550 | 1.20 (1.12–1.29) | 12 |
| Michailidou et al. (2017) | Breast cancer | European | Illumina | Multiple | 61,282 | 45,494 | 1.06 (1.04–1.08) | 13 |
| Zhang et al. (2017) | HCC | Asian | MassArray | HB | 473 | 564 | 0.75 (0.59–0.96) | 8 |
| Wu, Yan, et al. (2017) | Esophageal cancer | Asian | MassArray | HB | 386 | 495 | 1.70 (1.33–2.18) | 6 |
| Ye et al. (2017) | Lung cancer | Asian | MassArray | PB | 554 | 603 | 1.41 (1.14–1.76) | 8 |
| Wu, Zhu, et al. (2017) | RCC | Asian | MassArray | PB | 293 | 459 | 1.39 (1.07–1.81) | 6 |
| Melin et al. (2017) | Glioma | European | Illumina | Multiple | 1591 | 804 | 1.40 (1.20–1.63) | 10 |
| Phelan et al. (2017) | Ovarian cancer | European | Illumina | Multiple | 16,924 | 68,502 | 1.08 (1.05–1.11) | 14 |
| Kuchenbaecker et al. (2015) | Ovarian cancer | European | Illumina | Multiple | 30,845 | 9,627 | 1.14 (1.10–1.19) | 12 |
| Li et al. (2017) | Colorectal cancer | Asian | MassArray | PB | 247 | 300 | 1.30 (0.94–1.80) | 5 |
| Lee et al. (2016) | Ovarian cancer | Multiple | Illumina | PB | 1,414 | 4,051 | 1.14 (1.03–1.26) | 13 |
| Earp et al. (2016) | Ovarian cancer | European | Affymetrix | Multiple | 3,573 | 5,640 | 1.14 (1.06–1.22) | 12 |
| Martino et al. (2016) | RCC | European | Agarose gel electrophoresis | PB | 243 | 420 | 1.20 (0.93–1.55) | 5 |
| Zhang et al. (2016) | NPC | Asian | MassArray | PB | 855 | 1,036 | 1.16 (0.96–1.41) | 10 |
| Wang et al. (2016) | Lung cancer | Asian | MassArray | HB | 228 | 301 | 1.34 (0.98–1.83) | 6 |
| Duan et al. (2016) | Gastric cancer | Asian | MassArray | HB | 302 | 300 | 1.56 (1.15–2.11) | 6 |
| Huo et al. (2016) | Breast cancer | African | Illumina | PB | 6,657 | 7,713 | 1.13 (1.07–1.19) | 13 |
| Gong et al. (2016) | Thyroid cancer | Asian | PCR‐RFLP | HB | 452 | 452 | 1.38 (1.10–1.72) | 7 |
| Zhang et al. (2015) | GISTs | Asian | TaqMan | HB | 300 | 300 | 1.40 (1.04–1.88) | 6 |
| Michailidou et al. (2015) | Breast cancer | European | TaqMan | Multiple | 62,533 | 60,976 | 1.06 (1.04–1.09) | 14 |
| Campa, Rizzato, et al. (2015) | Multiple myeloma | European | TaqMan | PB | 2,267 | 2,796 | 0.88 (0.79–0.97) | 11 |
| Shadrina et al. (2015) | NHL | European | TaqMan | PB | 344 | 893 | 1.01 (0.83–1.24) | 8 |
| Shadrina et al. (2015) | DLBCL | European | TaqMan | PB | 139 | 893 | 0.85 (0.63–1.16) | 7 |
| Shadrina et al. (2015) | SLL/CLL | European | TaqMan | PB | 77 | 893 | 1.21 (0.84–1.73) | 5 |
| Campa, Rizzato, et al. (2015) | Pancreatic cancer | European | Illumina | Multiple | 1901 | 4,106 | 0.95 (0.87–1.05) | 12 |
| Panagiotou et al. (2015) | Prostate cancer | European | Illumina | Multiple | 23,631 | 24,534 | 1.15 (1.12–1.19) | 13 |
| Speedy et al. (2014) | Leukemia | Multiple | Illumina | Multiple | 2,883 | 8,350 | 1.03 (0.96–1.10) | 11 |
| Llorca‐Cardenosa et al. (2014) | Melanoma | European | KASPtechnology | HB | 648 | 381 | 1.02 (0.83–1.23) | 8 |
| Gao et al. (2014) | Lung cancer | Asian | MassArray | HB | 309 | 310 | 1.28 (0.96–1.71) | 6 |
| Long et al. (2013) | Breast cancer | African | Illumina | Multiple | 1,112 | 930 | 0.86 (0.75–0.97) | 11 |
| Palmer et al. (2013) | Breast cancer | African‐American | MassArray | Multiple | 1,199 | 1948 | 1.05 (0.94–1.17) | 12 |
| Garcia‐Closas et al. (2013) | Breast cancer | European | Illumina | Multiple | 4,193 | 35,194 | 1.15 (1.11–1.20) | 14 |
| Purrington et al. (2013) | Breast cancer | Multiple | Illumina | Multiple | 3,677 | 4,708 | 1.24 (1.14–1.34) | 11 |
| Bojesen et al. (2013) | Breast cancer | European | Illumina | Multiple | 46,451 | 42,599 | 1.06 (1.04–1.08) | 14 |
| Bojesen et al. (2013) | Breast cancer | Asian | Illumina | Multiple | 6,269 | 6,624 | 1.04 (0.98–1.10) | 13 |
| Bojesen et al. (2013) | Breast cancer | African‐American | Illumina | Multiple | 1,116 | 932 | 1.19 (1.05–1.35) | 10 |
| Bojesen et al. (2013) | Ovarian cancer | European | Illumina | Multiple | 986 | 23,491 | 1.33 (1.20–1.47) | 12 |
| Bojesen et al. (2013) | Ovarian cancer | European | Illumina | Multiple | 8,371 | 23,491 | 1.15 (1.11–1.20) | 13 |
| Zhao et al. (2013) | Lung cancer | Asian | SNPscanTM | PB | 784 | 782 | 1.14 (0.98–1.32) | 9 |
| Pellatt et al. (2013) | Colorectal cancer | Multiple | Illumina | PB | 2,309 | 2,915 | 1.06 (0.97–1.15) | 12 |
| Schumacher et al. (2013) | TGCTs | European | TaqMan | Multiple | 940 | 1559 | 0.66 (0.53–0.82) | 10 |
| Terry et al. (2012) | Ovarian cancer | Multiple | TaqMan | Multiple | 2,112 | 2,456 | 1.11 (1.00–1.23) | 11 |
| Sheng et al. (2013) | leukemia | Asian | TaqMan | HB | 570 | 673 | 1.27 (1.04–1.56) | 10 |
| Haiman et al. (2011) | Breast cancer | African‐American | Illumina | Multiple | 1,002 | 2,743 | 0.76 (0.68–0.84) | 12 |
| Haiman et al. (2011) | Breast cancer | European | Illumina | Multiple | 5,007 | 17,965 | 1.19 (1.13–1.25) | 14 |
| Zhao et al. (2011) | Glioma | Asian | MassArray | HB | 983 | 1,024 | 0.99 (0.84–1.18) | 12 |
| Schumacher et al. (2011) | Prostate cancer | Multiple | Illumina | Multiple | 2,782 | 4,458 | 0.80 (0.73–0.89) | 11 |
| Petersen et al. (2010) | Pancreatic cancer | European | Illumina | Multiple | 3,851 | 3,934 | 0.91 (0.83–1.00) | 10 |
| Rothman et al. (2010) | Bladder cancer | European | Illumina | Multiple | 3,532 | 5,120 | 0.90 (0.84–0.96) | 12 |
| Prescott et al. (2010) | Endometrial cancer | Caucasian | TaqMan | PB | 674 | 1685 | 1.08 (0.92–1.26) | 10 |
| Landi et al. (2009) | Lung cancer | European | Illumina | Multiple | 5,739 | 5,848 | 1.02 (0.95–1.10) | 13 |
Abbreviations: 95% CI: 95% confidence interval; DLBCL, diffuse Large B‐cell lymphoma; GCA, gastric cardia adenocarcinoma; GISTs, gastrointestinal stromal tumors; HB, hospital based; HCC, hepatocellular carcinoma; NHL, non‐Hodgkin's lymphomas; NPC, nasopharyngeal carcinoma; OR, odds ratio; PB, population based; PCR‐RFLP, polymerase chain reaction‐restriction fragment length polymorphism; RCC, renal cell carcinoma; SLL/CLL, small lymphocytic lymphoma/chronic lymphocytic leukemia; TGCTs, testicular germ cell tumors.